$701 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 131 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | New | SPDR SERIES TRUSTput | $121,198,000 | – | 1,400,000 | +100.0% | 17.29% | – |
| CELJF | New | CELLCOM ISRAEL LTD | $14,301,000 | – | 1,535,988 | +100.0% | 2.04% | – |
| AGN | New | ALLERGAN PLC | $12,297,000 | – | 60,000 | +100.0% | 1.75% | – |
| TEVA | New | TEVA PHARMACEUTICAL INDS LTDsponsored adr | $7,040,000 | – | 400,000 | +100.0% | 1.00% | – |
| SRPT | New | SAREPTA THERAPEUTICS INCcall | $6,804,000 | – | 150,000 | +100.0% | 0.97% | – |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $6,376,000 | – | 205,000 | +100.0% | 0.91% | – |
| ZGNX | New | ZOGENIX INC | $5,082,000 | – | 145,000 | +100.0% | 0.72% | – |
| MYL | New | MYLAN N Vcall | $4,706,000 | – | 150,000 | +100.0% | 0.67% | – |
| INSM | New | INSMED INC | $4,213,000 | – | 135,000 | +100.0% | 0.60% | – |
| GLD | New | SPDR GOLD TRUST | $4,035,000 | – | 33,190 | +100.0% | 0.58% | – |
| KDMN | New | KADMON HLDGS INC | $3,685,000 | – | 1,100,000 | +100.0% | 0.53% | – |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $3,166,000 | – | 20,823 | +100.0% | 0.45% | – |
| PANW | New | PALO ALTO NETWORKS INC | $2,998,000 | – | 20,805 | +100.0% | 0.43% | – |
| ANAB | New | ANAPTYSBIO INC | $2,796,000 | – | 80,000 | +100.0% | 0.40% | – |
| CMTA | New | CLEMENTIA PHARMACEUTICALS IN | $2,753,000 | – | 163,000 | +100.0% | 0.39% | – |
| CTIC | New | CTI BIOPHARMA CORP | $2,659,000 | – | 833,633 | +100.0% | 0.38% | – |
| CMCSA | New | COMCAST CORP NEWcl a | $2,554,000 | – | 66,360 | +100.0% | 0.36% | – |
| FLKS | New | FLEX PHARMA INC | $2,341,000 | – | 141,300 | +100.0% | 0.33% | – |
| CTSH | New | COGNIZANT TECHNOLOGY SOLUTIOcl a | $2,239,000 | – | 30,866 | +100.0% | 0.32% | – |
| ORLY | New | O REILLY AUTOMOTIVE INC NEWcall | $2,154,000 | – | 10,000 | +100.0% | 0.31% | – |
| AAP | New | ADVANCE AUTO PARTS INCcall | $2,083,000 | – | 21,000 | +100.0% | 0.30% | – |
| AXGT | New | AXOVANT SCIENCES LTDput | $2,064,000 | – | 300,000 | +100.0% | 0.29% | – |
| NITE | New | NIGHTSTAR THERAPEUTICS PLCadr | $1,728,000 | – | 90,000 | +100.0% | 0.25% | – |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $1,636,000 | – | 40,000 | +100.0% | 0.23% | – |
| CYTK | New | CYTOKINETICS INCcall | $1,450,000 | – | 100,000 | +100.0% | 0.21% | – |
| DCPH | New | DECIPHERA PHARMACEUTICALS IN | $1,424,000 | – | 75,000 | +100.0% | 0.20% | – |
| ACHN | New | ACHILLION PHARMACEUTICALS IN | $1,347,000 | – | 300,000 | +100.0% | 0.19% | – |
| TEVA | New | TEVA PHARMACEUTICAL INDS LTDput | $1,267,000 | – | 72,000 | +100.0% | 0.18% | – |
| AXGT | New | AXOVANT SCIENCES LTDcall | $1,238,000 | – | 180,000 | +100.0% | 0.18% | – |
| NCNA | New | NUCANA PLCsponsored adr | $919,000 | – | 50,000 | +100.0% | 0.13% | – |
| VKTX | New | VIKING THERAPEUTICS INC | $554,000 | – | 290,000 | +100.0% | 0.08% | – |
| ORLY | New | O REILLY AUTOMOTIVE INC NEW | $366,000 | – | 1,700 | +100.0% | 0.05% | – |
| AAP | New | ADVANCE AUTO PARTS INC | $266,000 | – | 2,686 | +100.0% | 0.04% | – |
| SAGE | New | SAGE THERAPEUTICS INCput | $150,000 | – | 2,400 | +100.0% | 0.02% | – |
| ATHX | New | ATHERSYS INC | $2,000 | – | 773 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2017-11-27
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.